Publications
359
Citations
5,006
Est. group size
~45
Recurring co-author estimate
Active years
18
Publishing since 2009
Benjamin H. Kaffenberger's research focuses on complex and severe skin conditions, especially pyoderma gangrenosum (a rare inflammatory skin ulcer disease) and severe drug reactions like Stevens-Johnson syndrome and toxic epidermal necrolysis. His work spans clinical outcomes research, genetic risk factors (such as HLA gene variants linked to drug reactions), and hospital-based dermatology care patterns, often using large multicenter or registry datasets.
Publication output has grown substantially over the past decade, rising from about 12 papers per year in 2017 to over 40 per year by 2023-2024, with a slight decline in 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Outpatient care activities of inpatient dermatologists between 2013-2019 reveal unique practice patterns
Journal of the American Academy of Dermatology · 2026
- Validation of PARACELSUS score performance for the diagnosis of pyoderma gangrenosum: An international multicenter study with 1403 cases
Journal of the American Academy of Dermatology · 2026
- Attendance at a Post‐Discharge Dermatology Clinic Is Associated With Reduced Rehospitalization Risk for Primary Dermatologic Conditions
International Journal of Dermatology · 2026
- HLA-B Alleles With Shared Peptide Binding Specificities Define Global Risk of Co-trimoxazole-Induced Severe Cutaneous Adverse Drug Reactions
The Journal of Allergy and Clinical Immunology In Practice · 2025
- HLA-B*58:01 and Risk of Allopurinol-Induced Severe Cutaneous Adverse Reactions in the US
JAMA Dermatology · 2025
- Recovering From Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
JAMA Dermatology · 2025
- Pyoderma gangrenosum refined elements for core item selection and evaluation (PRECISE-PG): a study protocol for reaching consensus on core outcome domain items in clinical trials of pyoderma gangrenosum
Archives of Dermatological Research · 2025
- Clinical Characteristics, Treatments, and Outcomes of Pyoderma Gangrenosum of the Face: A Systematic Review
International Wound Journal · 2025
- Part B of the LILAC study of litifilimab for cutaneous lupus erythematosus: a plain language summary
Immunotherapy · 2025
- HLA-B Alleles with Shared Peptide Binding Specificities Define Global Risk of Cotrimoxazole-induced SCAR
medRxiv · 2025
- Cutaneous ulcers in patients with chronic graft-versus-host disease: A systematic review
JAAD reviews. · 2025
- Evaluation and Treatment of Elevated Bile Acids in Chronic Pruritus of the Elderly: A Case Series
International Journal of Dermatology · 2025
- 64770 Characterization of patient perception of odor severity in hidradenitis suppurativa using TARGET-DERM HS
Journal of the American Academy of Dermatology · 2025
- 63560 Vilobelimab Safety in Pyoderma Gangrenosum Patients: A Phase 2a Explorative Dose-Finding Study
Journal of the American Academy of Dermatology · 2025
- 64241 Testing Bile Acids Versus Bilirubin in Chronic Pruritus: Evaluating Diagnostic and Therapeutic Implications
Journal of the American Academy of Dermatology · 2025
- Journal of the American Academy of Dermatology×74
- International Journal of Dermatology×39
- Archives of Dermatological Research×26
- Journal of Investigative Dermatology×23
- JAMA Dermatology×17
- Kelsey B. Nusbaum
Medicine · The Ohio State University
- Abraham M. Korman
Medicine · The Ohio State University
- Allison Yan
Medicine · The Ohio State University
- Ty Gilkey
Medicine · The Ohio State University
- Abraham M. Korman
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile